Patient Square Capital LP Takes $2.31 Million Position in Enliven Therapeutics, Inc. (NASDAQ:ELVN)

Patient Square Capital LP acquired a new stake in Enliven Therapeutics, Inc. (NASDAQ:ELVN - Free Report) in the third quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm acquired 90,572 shares of the company's stock, valued at approximately $2,313,000. Enliven Therapeutics accounts for about 0.9% of Patient Square Capital LP's portfolio, making the stock its 9th largest holding. Patient Square Capital LP owned approximately 0.19% of Enliven Therapeutics as of its most recent filing with the Securities & Exchange Commission.

A number of other hedge funds have also recently added to or reduced their stakes in the company. Quest Partners LLC boosted its position in shares of Enliven Therapeutics by 87.3% during the second quarter. Quest Partners LLC now owns 1,592 shares of the company's stock valued at $37,000 after buying an additional 742 shares during the last quarter. China Universal Asset Management Co. Ltd. boosted its position in shares of Enliven Therapeutics by 64.4% during the third quarter. China Universal Asset Management Co. Ltd. now owns 9,085 shares of the company's stock valued at $232,000 after buying an additional 3,559 shares during the last quarter. SG Americas Securities LLC purchased a new position in Enliven Therapeutics in the third quarter worth $256,000. Verition Fund Management LLC bought a new position in Enliven Therapeutics in the 3rd quarter valued at $271,000. Finally, The Manufacturers Life Insurance Company bought a new position in Enliven Therapeutics in the 2nd quarter valued at $322,000. Institutional investors and hedge funds own 95.08% of the company's stock.

Enliven Therapeutics Stock Up 0.4 %

ELVN traded up $0.10 during trading on Wednesday, reaching $23.71. 118,877 shares of the company were exchanged, compared to its average volume of 256,671. The company's 50-day moving average is $26.79 and its two-hundred day moving average is $24.14. The company has a market cap of $1.16 billion, a price-to-earnings ratio of -12.38 and a beta of 1.02. Enliven Therapeutics, Inc. has a 12-month low of $9.80 and a 12-month high of $30.03.

Analyst Upgrades and Downgrades

A number of research analysts have issued reports on ELVN shares. Robert W. Baird upped their price objective on Enliven Therapeutics from $32.00 to $40.00 and gave the company an "outperform" rating in a research note on Friday, November 15th. HC Wainwright restated a "buy" rating and issued a $37.00 price objective on shares of Enliven Therapeutics in a research note on Tuesday, October 1st.

Insider Buying and Selling

In other Enliven Therapeutics news, insider Joseph P. Lyssikatos sold 847 shares of the firm's stock in a transaction dated Friday, October 18th. The stock was sold at an average price of $30.00, for a total value of $25,410.00. Following the sale, the insider now owns 1,015,188 shares of the company's stock, valued at $30,455,640. This trade represents a 0.08 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Also, CFO Benjamin Hohl sold 5,250 shares of the firm's stock in a transaction dated Wednesday, November 27th. The shares were sold at an average price of $24.89, for a total value of $130,672.50. The disclosure for this sale can be found here. In the last quarter, insiders have sold 129,195 shares of company stock valued at $3,581,772. Corporate insiders own 29.20% of the company's stock.

About Enliven Therapeutics

Enliven Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule inhibitors to help patients with cancer. The company's lead product candidates comprise ELVN-001, which is being evaluated in a Phase 1 clinical trial in adults with chronic myeloid leukemia; and ELVN-002, a Phase 1 clinical trial in adults with solid tumors with HER2 alterations.